Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 10/20 | 0.37 |
| ▸ | BCAT2 | O15382 | 8/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 3/20 | 0.32 |
| ▸ | MAT2A | P31153 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243419 | 0.89 | BCAT1 (0.33) | BCAT1BCAT2DHODHP2RY1PPARG | |
| SCHEMBL2594502 | 0.89 | BCAT1 (0.41) | BCAT1BCAT2HDAC1HDAC8HDAC6 | |
| SCHEMBL3248273 | 0.89 | PKM (0.34) | BCAT1BCAT2P2RY1PPARG | |
| SCHEMBL3250960 | 0.88 | DHODH (0.34) | BCAT1DHODHP2RY1 | |
| SCHEMBL3243364 | 0.87 | BCAT1 (0.33) | BCAT1BCAT2DHODHP2RY1PPARG | |
| SCHEMBL6635615 | 0.86 | BCAT1 (0.34) | BCAT1BCAT2GRIN1GRIN2BP2RY1 | |
| SCHEMBL2582563 | 0.86 | ALDH1A1 (0.40) | BCAT1BCAT2HDAC1HDAC8HDAC6 | |
| SCHEMBL13397734 | 0.85 | DHODH (0.32) | BCAT1DHODHP2RY1 | |
| SCHEMBL3955892 | 0.85 | DHODH (0.33) | BCAT1DHODH | |
| SCHEMBL5914268 | 0.84 | BCAT1 (0.34) | BCAT1BCAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011137088-A1 | HERBICIDAL URACILS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-11-03 | — | — | WO | disclosed |
| EP-1422227-B1 | PROCESS FOR PRODUCING PYRIDINE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2009-09-09 | — | — | EP | disclosed |
| US-7223862-B2 | Pyridone compounds useful for producing pyridine compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-29 | — | — | US | disclosed |
| US-7157579-B2 | Process for producing pyridine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20060189484-A1 | PYRIDONE COMPOUNDS USEFUL FOR PRODUCING PYRIDINE COMPOUNDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20040254077-A1 | Process for producing pyridine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1422227-A1 | PROCESS FOR PRODUCING PYRIDINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254077-A1 | Process for producing pyridine compound | CBR1, CBR3, CYP4B1 | BCAT1 1753/4885BCAT2 1515/4885HDAC1 1079/4885 |
| US-20060189484-A1 | PYRIDONE COMPOUNDS USEFUL FOR PRODUCING PYRIDINE COMPOUNDS | CBR3, CBR1, PNPO | BCAT1 1359/4885BCAT2 1679/4885HDAC1 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.